Compare CNS & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | WGS |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2004 | N/A |
| Metric | CNS | WGS |
|---|---|---|
| Price | $63.27 | $70.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $72.50 | ★ $140.71 |
| AVG Volume (30 Days) | 242.1K | ★ 714.0K |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $427,536,000.00 | N/A |
| Revenue This Year | $7.83 | $29.98 |
| Revenue Next Year | $11.02 | $24.85 |
| P/E Ratio | ★ $21.35 | $1,251.58 |
| Revenue Growth | ★ 4.07 | N/A |
| 52 Week Low | $58.39 | $55.17 |
| 52 Week High | $82.24 | $170.87 |
| Indicator | CNS | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 34.67 |
| Support Level | $59.65 | $68.55 |
| Resistance Level | $64.43 | $76.21 |
| Average True Range (ATR) | 2.04 | 5.43 |
| MACD | -0.30 | -0.20 |
| Stochastic Oscillator | 30.73 | 7.04 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.